We are monitoring the impact of COVID-19 on Urinary Tract Infections Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 4389
Share on
Share on

Global Urinary Tract Infections Market Size, Share, Trends and Growth Analysis Report - By Type of Medication, Type of Indication and Region – Industry Forecast (2020 to 2025)

Pulished: February, 2020
ID: 4389
Pages: 175

Global Urinary Tract Infections Market Size (2020 to 2025)

The global urinary tract infections market is forecasted at USD 10.07 billion in 2020 and is estimated to be growing at a CAGR of 2.14%, to reach USD 11.19 billion by 2025.

Urinary Tract Infection is an infection that affects parts of the urinary tract. When it affects the lower urinary tract, it is called a bladder infection or cystitis, and when it affects the upper urinary tract, it is called kidney infection or pyelonephritis. A UTI can happen anywhere in your urinary tract. Your urinary tract is made up of your kidneys, ureters, bladder, and urethra. Most UTIs only involve the urethra and bladder in the lower tract. However, UTIs can involve the ureters and kidneys in the upper tract. Although upper tract UTIs are rarer than lower tract UTIs, they’re also usually more severe. UTI symptoms are burning, increased frequency of urination, bloody urine, pelvic pain in women, rectal pain in men, urine that looks like cola or tea. Today Urinary Tract Infections are most common in women. 

The most common cause of infection is E coli, though other fungi or bacteria may rarely be the cause. Risk factors include female anatomy, diabetes, obesity, sexual intercourse, and family history. Although sexual intercourse is a risk factor, urinary tract infections are not categorized as sexually transmitted infections. If kidney infection occurs, it usually follows a bladder infection and results from infection, which is blood-borne in nature. Diagnosis in young, healthy women can be based alone on symptoms. In those with vague symptoms, diagnosis is difficult since bacteria may be present without an infection. In complicated cases or when conventional treatments fail, a urine culture may be useful.

The driving factors of the global urinary tract infections market are the sudden rise in the prevalence rate and the disease's diagnosis. This has started the opportunities for major players to allocate their resources towards combination therapy research and development. This will surely result in the growth of market size during the forecast period. With the launch of new drugs for multiple indications under urinary tract infections and label expansion for already existing drugs, the market is expected to boost further. The generic, low-cost competition for some of the drugs is fierce and is forecasted to get more competitive and thus can contribute to offsetting the figures for the current market size.

Complicated regulatory monitoring hampers the urinary tract infections market. Several companies have prevented or reduced the research and development activities in advancing antibiotics as they have a low return on investments. The investments required for the research and development activities for new drugs and antibiotics are comparatively low. This factor is to limit the market growth. Lack of awareness regarding the frequent urinary tract infections in the developed and underdeveloped countries is restraining the market growth. The clinical trials for preparing antibacterial drugs are challenging and require an instructive, ethical, and scientific approach. The mentioned-above factor obstructs the market growth.

Impact of COVID-19 on the global urinary tract infections market:

The novel coronavirus (COVID 19), which turned into a worldwide pandemic, infected millions of people and caused thousands to death. The common comorbidity in COVID 19 positive patients is diabetes, chronic lung disease, and hypertension. People with 60 years and above or suffering from health conditions like diabetes, heart or lung disease, which affects their immune system, are more likely to suffer from COVID 19. Not only efficient of causing respiratory illness, but the COVID 19 may also damage the organ systems of the human body along with urogenital systems. The COVID 19 sensitivity may result in bladder dysfunction.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Type of Medication, Type of indication and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global urinary tract infections market has been segmented and sub-segmented based on the type of medication, type of indication, and region.

Urinary Tract Infections Market – By Type of Medication:

  • Penicillin & Combinations 
    • Amoxicillin
    • Amoxicillin-Clavulanate Potassium combination
  • Quinolones             
    • Ciprofloxacin
    • Levofloxacin
    • Norfloxacin
    • Nalidixic Acid
  • Aminoglycoside-Antibodies             
    • Gentamicin
    • Amikacin
  • Cephalosporin       
    • Ceftriaxone
    • Cefixime
    • Cefuroxime
    • Cephalexin
  • Sulphonamides     
    • Sulfamethoxazole
    • Trimethoprim combination
  • Azoles & Amphotericin B  
  • Tetracycline            
    • Doxycycline
    • Nitrofurans
  • Nitrofurans 

Based on the type of medication, the quinolones segment is expected to lead the global urinary tract infection market and held 37.7% of the share in 2019. Many physicians suggest the patients about the intake of quinolones get rid of their infection quickly.

The penicillin and combinations segments are predicted to grow at the highest CAGR growth rate during the forecast period.

Urinary Tract Infections Market – By Type of Indication:

  • Uncomplicated UTI
  • Complicated UTI   
  • Recurring Complicated UTI               
  • Neurogenic Bladder Infection  

Based on the type of indication, the complicated UTIs segment dominates the UTI and accounts to hold most of the market share. The segment growth depends on mushrooming drug-resistant bacteria and enormous usage of antibiotics. Many medical professionals prescribe quinolones for treating complicated urinary tract infections among patients—the regularity of complicated UTIs to escalate throughout the forecasting period. According to the Queensland Pediatric Factsheet 2019, around 1 in 10girls and 1 in 50 boys suffer from urinary tract infections by seven years of age.

Urinary Tract Infections Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, the Asia Pacific region has the largest market for urinary tract infections globally by share and is also the fastest-growing region, owing to factors such as rising rate of diagnostics, gradual adoption of improved technologies, emerging health care infrastructures, and increased disposable income. Europe and North America have the second and third largest market shares respectively.

KEY PARTICIPANTS IN THE MARKET:

Some of the noteworthy companies leading the global urinary tract infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd.

RECENT HAPPENINGS IN THIS MARKET:

  • In May 2020, Spero Therapeutics Inc. announced the completion of patient registration in its Phase-3 clinical trial ADAPT-PO, of tebipenem HBr. For treating patients suffering from complicated urinary tract infection (cUTI) and acute pyelonephritis (AP).
  • In December 2019, Johnson & Johnson acquired TARIS Biomedical LLC. TAR-200, the leading clinical-stage product, uses the proprietary TARIS system that looks like a silicone-based drug delivery device and ensures the on-going release of medication into the bladder.
  • In October 2019, Cipla acquired Elores from Venus Remedies Ltd. Elores drug used for treating life-threatening infections, and the medicine is to fight against anti-microbial resistance. According to the latest Phase-3 clinical study, Elores proved to be primary to meropenem for treating patients suffering from complicated urinary tract infections.
  • In July 2019, Pfizer Inc. completed its acquisition of Array BioPharnma Inc. Array BioPharma became a part of Pfizer, adding a splendid portfolio, including the approved combined usage BRAFTOVI and MEKTOVI.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Type of Medication                 

                                5.1.1 Penicillin & Combinations 

                                                5.1.1.1 Amoxicillin

                                                5.1.1.2 Amoxicillin-Clavulanate Potassium combination

                                5.1.2 Quinolones             

                                                5.1.2.1 Ciprofloxacin

                                                5.1.2.2 Levofloxacin

                                                5.1.2.3 Norfloxacin

                                                5.1.2.4 Nalidixic Acid

                                5.1.3 Aminoglycoside-Antibodies             

                                                5.1.3.1 Gentamicin

                                                5.1.3.2 Amikacin

                                5.1.4 Cephalosporin       

                                                5.1.4.1 Ceftriaxone

                                                5.1.4.2 Cefixime

                                                5.1.4.3 Cefuroxime

                                                5.1.4.4 Cephalexin

                                5.1.5 Sulphonamides     

                                                5.1.5.1 Sulfamethoxazole

                                                5.1.5.2 Trimethoprim combination

                                5.1.6 Azoles & Amphotericin B  

                                5.1.7 Tetracycline            

                                                5.1.7.1 Doxycycline

                                                5.1.7.2 Nitrofurans

                                5.1.8 Nitrofurans             

                                5.1.9  Y-o-Y Growth Analysis, By Type of Medication       

                                5.1.10  Market Attractiveness Analysis, By Type of Medication   

                                5.1.11  Market Share Analysis, By Type of Medication    

                5.2 Type of Indication                    

                                5.2.1 Uncomplicated UTI              

                                5.2.2 Complicated UTI   

                                5.2.3 Recurring Complicated UTI               

                                5.2.4 Neurogenic Bladder Infection         

                                5.2.5 Y-o-Y Growth Analysis, By Type of Indication           

                                5.2.6 Market Attractiveness Analysis, By Type of Indication         

                                5.2.7 Market Share Analysis, By Type of Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Type of Medication

                                                6.1.3.2 By Type of Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Type of Medication

                                                6.1.4.2 By Type of Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Type of Medication

                                                6.1.5.2 By Type of Indication

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Pfizer, Inc.                   

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 AstraZeneca plc                        

                8.3 Johnson & Johnson                 

                8.4 Novartis International AG.                   

                8.5 F. Hoffmann La Roche Ltd.                   

                8.6 Teva Pharmaceutical Industries Ltd.                

                8.7 Boehringer Ingelheim GmbH                              

                8.8 Cipla Ltd.                      

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms by type, packaging and meat type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economic and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Urinary Tract Infections Market, By Region, From 2020 to 2025 (USD Million)
  2. Global Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  3. Global Penicillin & Combinations Market, By Region, From 2020 to 2025 (USD Million)
  4. Global Quinolones Market, By Region, From 2020 to 2025 (USD Million)
  5. Global Aminoglycoside-Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  6. Global Cephalosporin Market, By Region, From 2020 to 2025 (USD Million)
  7. Global Sulphonamides Market, By Region, From 2020 to 2025 (USD Million)
  8. Global Azoles & Amphotericin B Market, By Region, From 2020 to 2025 (USD Million)
  9. Global Tetracycline  Market, By Region, From 2020 to 2025 (USD Million)
  10. Global Nitrofurans Market, By Region, From 2020 to 2025 (USD Million)
  11. Global Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  12. Global Uncomplicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  13. Global Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  14. Global Recurring Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  15. Global Neurogenic Bladder Infection Market, By Region, From 2020 to 2025 (USD Million)
  16. North America Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  17. North America Penicillin & Combinations Market, By Region, From 2020 to 2025 (USD Million)
  18. North America Quinolones Market, By Region, From 2020 to 2025 (USD Million)
  19. North America Aminoglycoside-Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  20. North America Cephalosporin Market, By Region, From 2020 to 2025 (USD Million)
  21. North America Sulphonamides Market, By Region, From 2020 to 2025 (USD Million)
  22. North America Azoles & Amphotericin B Market, By Region, From 2020 to 2025 (USD Million)
  23. North America Tetracycline  Market, By Region, From 2020 to 2025 (USD Million)
  24. North America Nitrofurans Market, By Region, From 2020 to 2025 (USD Million)
  25. North America Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  26. North America Uncomplicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  27. North America Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  28. North America Recurring Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  29. North America Neurogenic Bladder Infection Market, By Region, From 2020 to 2025 (USD Million)
  30. United States Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  31. United States Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  32. Canada Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  33. Canada Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  34. Europe Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  35. Europe Penicillin & Combinations Market, By Region, From 2020 to 2025 (USD Million)
  36. Europe Quinolones Market, By Region, From 2020 to 2025 (USD Million)
  37. Europe Aminoglycoside-Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  38. Europe Cephalosporin Market, By Region, From 2020 to 2025 (USD Million)
  39. Europe Sulphonamides Market, By Region, From 2020 to 2025 (USD Million)
  40. Europe Azoles & Amphotericin B Market, By Region, From 2020 to 2025 (USD Million)
  41. Europe Tetracycline  Market, By Region, From 2020 to 2025 (USD Million)
  42. Europe Nitrofurans Market, By Region, From 2020 to 2025 (USD Million)
  43. Europe Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  44. Europe Uncomplicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  45. Europe Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  46. Europe Recurring Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  47. Europe Neurogenic Bladder Infection Market, By Region, From 2020 to 2025 (USD Million)
  48. U.K. Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  49. U.K. Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  50. Germany Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  51. Germany Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  52. France Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  53. France Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  54. Italy Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  55. Italy Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  56. Spain Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  57. Spain Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  58. Asia Pacific Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  59. Asia Pacific Penicillin & Combinations Market, By Region, From 2020 to 2025 (USD Million)
  60. Asia Pacific Quinolones Market, By Region, From 2020 to 2025 (USD Million)
  61. Asia Pacific Aminoglycoside-Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  62. Asia Pacific Cephalosporin Market, By Region, From 2020 to 2025 (USD Million)
  63. Asia Pacific Sulphonamides Market, By Region, From 2020 to 2025 (USD Million)
  64. Asia Pacific Azoles & Amphotericin B Market, By Region, From 2020 to 2025 (USD Million)
  65. Asia Pacific Tetracycline  Market, By Region, From 2020 to 2025 (USD Million)
  66. Asia Pacific Nitrofurans Market, By Region, From 2020 to 2025 (USD Million)
  67. Asia Pacific Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  68. Asia Pacific Uncomplicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  69. Asia Pacific Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  70. Asia Pacific Recurring Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  71. Asia Pacific Neurogenic Bladder Infection Market, By Region, From 2020 to 2025 (USD Million)
  72. Japan Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  73. Japan Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  74. China Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  75. China Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  76. India Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  77. India Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  78. Australia Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  79. Australia Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  80. South Korea Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  81. South Korea Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  82. Latin America Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  83. Latin America Penicillin & Combinations Market, By Region, From 2020 to 2025 (USD Million)
  84. Latin America Quinolones Market, By Region, From 2020 to 2025 (USD Million)
  85. Latin America Aminoglycoside-Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  86. Latin America Cephalosporin Market, By Region, From 2020 to 2025 (USD Million)
  87. Latin America Sulphonamides Market, By Region, From 2020 to 2025 (USD Million)
  88. Latin America Azoles & Amphotericin B Market, By Region, From 2020 to 2025 (USD Million)
  89. Latin America Tetracycline  Market, By Region, From 2020 to 2025 (USD Million)
  90. Latin America Nitrofurans Market, By Region, From 2020 to 2025 (USD Million)
  91. Latin America Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  92. Latin America Uncomplicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  93. Latin America Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  94. Latin America Recurring Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  95. Latin America Neurogenic Bladder Infection Market, By Region, From 2020 to 2025 (USD Million)
  96. Brazil Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  97. Brazil Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  98. Argentina Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  99. Argentina Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  100. Mexico Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  101. Mexico Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  102. Rest of Latin America Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  103. Rest of Latin America Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  104. Middle East and Africa Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  105. Middle East and Africa Penicillin & Combinations Market, By Region, From 2020 to 2025 (USD Million)
  106. Middle East and Africa Quinolones Market, By Region, From 2020 to 2025 (USD Million)
  107. Middle East and Africa Aminoglycoside-Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  108. Middle East and Africa Cephalosporin Market, By Region, From 2020 to 2025 (USD Million)
  109. Middle East and Africa Sulphonamides Market, By Region, From 2020 to 2025 (USD Million)
  110. Middle East and Africa Azoles & Amphotericin B Market, By Region, From 2020 to 2025 (USD Million)
  111. Middle East and Africa Tetracycline Market, By Region, From 2020 to 2025 (USD Million)
  112. Middle East and Africa Nitrofurans Market, By Region, From 2020 to 2025 (USD Million)
  113. Middle East and Africa Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  114. Middle East and Africa Uncomplicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  115. Middle East and Africa Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  116. Middle East and Africa Recurring Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  117. Middle East and Africa Neurogenic Bladder Infection Market, By Region, From 2020 to 2025 (USD Million)
  118. Middle East Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  119. Middle East Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  120. Africa Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  121. Africa Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample